Abstract
Rituximab is a humanized monoclonal antibody directed against CD20-positive B cells and originally developed for the treatment of non-Hodgkins lymphoma. We report a case of severe mucous membrane pemphigoid responsive to rituximab infusions. The clinical presentation, etiology, and management options for mucous membrane pemphigoid are also discussed.
MeSH terms
-
Adult
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Murine-Derived
-
Antigens, CD20 / immunology*
-
Chemotherapy, Adjuvant / methods
-
Humans
-
Immunologic Factors / administration & dosage
-
Immunologic Factors / therapeutic use
-
Infusions, Intravenous
-
Male
-
Pemphigoid, Benign Mucous Membrane / drug therapy*
-
Pemphigoid, Benign Mucous Membrane / pathology
-
Rituximab
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Antigens, CD20
-
Immunologic Factors
-
Rituximab